New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
10:37 EDTCVC, MSTX, SALE, CHGG, DLPH, ZGNX, ALLTHigh option volume stocks
High option volume stocks: ALLT CHGG MSTX NBL ZGNX SALE JNUG CVC DLPH
News For ALLT;CHGG;MSTX;ZGNX;SALE;CVC;DLPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
10:03 EDTSALEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
May 27, 2015
16:20 EDTSALERetailMeNot initiated with a Buy at Topeka
Target $28.
08:44 EDTZGNXZogenix announces new efficacy data from study of low-dose fenfluramine
Zogenix announced new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria. Zogenix intends to initiate Phase 3 clinical studies for ZX008, the company's investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome. The results presented are from the latest 5-year follow-up period in a group of Dravet syndrome patients being treated with low-dose fenfluramine. This analysis, which includes ten patients from the original study group and two patients who began treatment in 2011, demonstrated that during any given year of the follow-up period, at least 80% of patients achieved a greater than or equal to 75% reduction in the frequency of seizures. In addition, three patients were seizure-free for all 5 years and five patients were seizure-free for 2 to 4 years. The use of low-dose fenfluramine in this group of patients was shown to be generally well tolerated, with the most common adverse events being transient loss of appetite and fatigue/somnolence. No clinically meaningful cardiac adverse events were noted. No patient discontinued treatment due to adverse events. In addition, a recently published translational research study to elucidate fenfluramine's mechanism of action in Dravet syndrome demonstrated the ability of fenfluramine to significantly reduce locomotion and eliminate epileptiform EEG activity in a gene knockdown zebrafish model of Dravet syndrome. These data support the clinical results obtained in the Belgium cohort of patients.
06:06 EDTCVCCablevision implied volatility of 45 at upper end of index
May 26, 2015
11:54 EDTCVCOptions with increasing implied volatility
Options with increasing implied volatility: VIPS DGX CVC JIVE LBTYA BBBY YHOO NKE CAN DTV
08:59 EDTCVCCablevision up more than 5% following Charter-TWC merger announcement
Subscribe for More Information
08:09 EDTMSTXMast Therapeutics initiates EPIC-E study
Subscribe for More Information
May 21, 2015
10:04 EDTCVCHigh option volume stocks
High option volume stocks: MTZ LQD LBTYA AGEN OCR CVC NTAP BBY BRKR VOC
May 20, 2015
16:26 EDTCVCOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:01 EDTCVCCablevision calls active as shares at four-year high
Cablevision June 21 and 23 calls are active on total call volume of 8K contracts (1K puts). June call option implied volatility is at 38, July is at 34 compared to its 90-day average of 34. Active call volume suggests traders taking positions for large upside price movement.
10:48 EDTCVCOptions with increasing implied volatility
Options with increasing implied volatility: WETF CVC YHOO NLY
10:23 EDTCVCCablevision rallies sharply, levels to watch
Subscribe for More Information
09:54 EDTCVCCablevision upgraded to Buy from Hold at Pivotal Research
Subscribe for More Information
May 15, 2015
17:15 EDTCVCPaulson & Co. gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use